[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-366865-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-366865-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-role-of-cytokines-in-ovarian-cancer-drug-resistance","The role of cytokines in ovarian cancer drug resistance","","Ovarian cancer is the leading cause of death among women diagnosed with female reproductive system cancers. Despite advances, progress over the past 20 years has been limited and treatment is not linear: many patients respond initially, yet about 80% relapse after one or more chemotherapy sessions. Cytokines drive tumor progression, relapse, and drug resistance in ovarian cancer. This review summarizes recent advances on cytokine-associated mechanisms and presents cytokine-targeting drugs, highlighting multi-pathway and multi-target strategies to overcome heterogeneous chemotherapy resistance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-role-of-cytokines-in-ovarian-cancer-drug-resistance/366865/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-role-of-cytokines-in-ovarian-cancer-drug-resistance/366865.png","ImageObject",300,407,{"name":42,"@type":43},"dhado","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is ovarian cancer difficult to treat in practice?","Question",{"text":63,"@type":64},"Ovarian cancer treatment progresses non-linearly; patients may respond initially, but relapse occurs in about 80% after one or more chemotherapy sessions.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role do cytokines play in ovarian cancer drug resistance?",{"text":68,"@type":64},"Cytokines promote tumor progression and contribute to relapse and drug resistance by inducing multiple pathways within the tumor microenvironment.",{"name":70,"@type":61,"acceptedAnswer":71},"What does the review focus on regarding therapeutic strategies?",{"text":72,"@type":64},"It summarizes recent advances in cytokine-associated mechanisms and discusses cytokine-targeting drugs, emphasizing the potential of multi-target approaches for chemotherapy resistance.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},366865,1790510860,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},5909893218464,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","DOI: 10.1002/ijc.70099  \nREVIE W  \nThe role of cytokines in ovarian cancer drug resistance  \nLu Wang 1,2 | Yunxia Zang 1,2,3 | Rebeka Dejenie 4 | Junyuan Bing 1,2,3 | Shixia Dong 2,3 | Yanfei Zhang 2,3 | Yi Zhu 4,5,6 | Jingjing Li 2,3,4  \n1School of Clinical Medicine, Shandong Second Medical University, Weifang, China  \n2Jinming Yu Academician Workstation of Oncology, Affiliated Hospital of Shandong Second Medical University, Weifang, China  \n3Affiliated Hospital of Shandong Second Medical University, School of Clinical Medicine, Shandong Second Medical University, Weifang, China 4University of Chicago Medical Center, Chicago, Illinois, USA  \n5Department of Orthopaedics, The First Affiliated Hospital of Soochow University, Suzhou, China 6Orthopaedic Institute, Medical College, Soochow University, Suzhou, China  \nCorrespondence  \nYi Zhu, Department of Orthopaedics, The First Affiliated Hospital of Soochow University, Orthopaedic Institute, Medical College, Soochow University, Suzhou 215007, China; The Molecular Oncology Laboratory, Department of Orthopaedic Surgery and Rehabilitation Medicine, The University of Chicago Medical Center, Chicago, IL 60637, USA.  \n[Email:](Email: yizhu06@uchicago.edu)[ yizhu06@uchicago.edu](Email: yizhu06@uchicago.edu)  \nJingjing Li, University of Chicago Medical Center, Chicago, IL, USA; Shandong Second Medical University, Weifang, China.  \nEmail: [jingjingli.md.phd@gmail.com](jingjingli.md.phd@gmail.com); [jingjinglimdphd@uchicago.edu](jingjinglimdphd@uchicago.edu)  \nFunding information  \nScience and Technology Project jointly established by the Science and Technology Department of the State Administration of Traditional Chinese Medicine, Grant/Award Number: GZY-KJS-SD-2023-079; Shandong Provincial Key Medical and Health Discipline of Oncology (Affiliated Hospital of Shandong Second Medical University); Shandong Provincial Health Commission, Grant/Award Number: M-2022053; National Natural Science Foundation of China, Grant/Award Number: 82104289; Yuandu Scholar Grant of Weifang City to LJJ, Science and Technology Innovation Plan from Weifang Medical  \nAbstract  \nOvarian cancer is the leading cause of death among women diagnosed with female reproductive system cancers. While significant advances have been made in treating various types of cancer, progress in ovarian cancer treatment over the past 20 years has been minimal, and the treatment course of ovarian cancer is not linear. Although many patients initially respond to treatment and may experience tumor regression, 80% of patients relapse after one or multiple chemotherapy sessions. Cytokines playa crucial role in driving tumor progression, relapse, and drug resistance in ovarian cancer. The knowledge of ovarian cancer drug resistance and the function of cytokines in the development of tumor resistance is currently the subject of numerous relevant studies; meanwhile, the specific molecular pathways are being unearthed. Herein, we summarize the recent advancements in cytokine-associated ovarian cancer drug resistance. In addition, we also present the cytokine targeting drugs in ameliorating ovarian cancer drug resistance. As multi-effect factors, cytokines can induce multiple pathways to promote tumor progression and overcome extremely complex and heterogeneous living environments. From the perspective of various paths of cytokine function, the emergence of multi-target drugs might be more promising for conquering ovarian cancer chemotherapy drug resistance.  \nKEYWOR DS  \ncytokine, drug resistance, IL6, ovarian cancer, tumor microenvironment  \nAbbreviations: AR, androgen receptor; CAFs, tumor-associated fibroblasts; CSCs, cancer stem cells; CSF-1, colony-stimulating factor; ECM, extracellular matrix; EMT, epithelial-to-mesenchymal transition; FAK, focal adhesion kinase; FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFNε, interferon-ε; IL- 4, interleukin-4; IL-6,","cbCaioPBqU1Q28od","https://ap.wps.com/l/cbCaioPBqU1Q28od","pdf",2933241,14,"English","# Abstract\n# Introduction\n## Background on ovarian cancer\n## Platinum-based chemotherapy and mechanisms","[{\"question\":\"Why is ovarian cancer difficult to treat in practice?\",\"answer\":\"Ovarian cancer treatment progresses non-linearly; patients may respond initially, but relapse occurs in about 80% after one or more chemotherapy sessions.\"},{\"question\":\"What role do cytokines play in ovarian cancer drug resistance?\",\"answer\":\"Cytokines promote tumor progression and contribute to relapse and drug resistance by inducing multiple pathways within the tumor microenvironment.\"},{\"question\":\"What does the review focus on regarding therapeutic strategies?\",\"answer\":\"It summarizes recent advances in cytokine-associated mechanisms and discusses cytokine-targeting drugs, emphasizing the potential of multi-target approaches for chemotherapy resistance.\"}]","The role of cytokines in ovarian cancer drug resistance | PDF",1790168000,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/af070702698a8794b35bf381cf8774ed.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/da266c9da6c8d65c8e645e2d2d1307d4.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/516b7a8de8ae221933baece2f4b618ae.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7329336f092624917a43c9b5dc682392.webp",980,1287]